NEKTAR THERAPEUTICS (NKTR) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for NEKTAR THERAPEUTICS (NKTR): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 41/100 — a percentile rank of NEKTAR THERAPEUTICS’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.
| Market cap | $1.6B |
| P / S | 29.4× |
| EV / EBITDA | -12.0× |
| Gross margin | 100.0% |
| Operating margin | -257.8% |
| Net margin | -287.8% |
| Return on equity | -17.4% |
| ROIC | -16.3% |
| Revenue growth | -27.2% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Is NEKTAR THERAPEUTICS overvalued? P/S looks overvalued vs its 5-year range; P/B looks fair vs its 5-year range.
Independent of the events above — derived from NEKTAR THERAPEUTICS’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact